Aproxi EZY Capsule 125 mg+80 mg+80 mg contains Aprepitant, a selective neurokinin-1 (NK1) receptor antagonist used for the prevention of chemotherapy-induced nausea and vomiting (CINV). This fixed-dose, multi-day regimen is designed to provide effective protection against both acute and delayed phases of nausea and vomiting associated with highly emetogenic cancer chemotherapy. It is used as part of combination antiemetic therapy for optimal patient comfort and treatment adherence.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Aprepitant 125 mg (Day 1 dose)
• Aprepitant 80 mg (Day 2 dose)
• Aprepitant 80 mg (Day 3 dose)

Mechanism of Action

Aprepitant works by selectively blocking neurokinin-1 (NK1) receptors in the central nervous system. These receptors bind to substance P, a key neurotransmitter involved in triggering nausea and vomiting. By inhibiting this pathway, Aproxi EZY effectively prevents both immediate and delayed chemotherapy-induced emesis, improving patient tolerance to cancer treatment.

Indications

Aproxi EZY Capsule is indicated for:

• Prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy
• Prevention of delayed nausea and vomiting following chemotherapy
• Use in combination with corticosteroids (such as dexamethasone) and 5-HT3 receptor antagonists (such as ondansetron)

Dosage and Administration

• Day 1: 125 mg capsule orally before chemotherapy
• Day 2: 80 mg capsule once daily
• Day 3: 80 mg capsule once daily
• Take with or without food
• Follow the full 3-day regimen exactly as prescribed
• Should always be used as part of combination antiemetic therapy

Benefits

• Provides strong protection against both acute and delayed chemotherapy-induced vomiting
• Improves patient comfort and quality of life during cancer treatment
• Enhances adherence to chemotherapy schedules
• Reduces need for rescue antiemetic medications
• Well-established regimen for high-risk chemotherapy protocols

Possible Side Effects

Common side effects may include:

• Fatigue
• Hiccups
• Constipation or diarrhea
• Dizziness
• Loss of appetite

Less common but serious side effects:

• Elevated liver enzymes
• Severe allergic reactions (rash, swelling, difficulty breathing)
• Drug interaction-related complications

Precautions and Warnings

• Use cautiously in patients with moderate to severe liver impairment
• Monitor for potential drug interactions due to CYP3A4 inhibition
• May reduce effectiveness of hormonal contraceptives
• Use only under oncology supervision
• Not recommended during pregnancy unless clearly necessary

Drug Interactions

• Significant interactions with CYP3A4-metabolized drugs
• May alter effects of corticosteroids, warfarin, and certain chemotherapy agents
• Concomitant use with pimozide or cisapride is contraindicated
• Inform physician about all ongoing medications

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

• Store below 30°C
• Protect from moisture and light
• Keep out of reach of children

Conclusion

Aproxi EZY Capsule 125 mg+80 mg+80 mg (Aprepitant) is an effective multi-day antiemetic regimen designed to prevent chemotherapy-induced nausea and vomiting. Its targeted NK1 receptor blockade provides strong protection during both acute and delayed phases, making it an essential supportive therapy in oncology care.